Discovery of zolinium TSG1180 as a novel agonist of transgelin-2 for treating asthma
文献类型：期刊论文
| 作者 | Yuan, Hong-Kai1; Li, Bo2,3,4; Wu, Leyun2,3,4; Wang, Xue-Ling1; Lv, Zhi-Ying1; Liu, Zhikai2,3; Xu, Zhijian2,3,4 ; Lu, Jin1; Chen, Cai-Tao1; Yang, Yong-Qing1
|
| 刊名 | Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
 |
| 出版日期 | 2023-11-01 |
| 卷号 | 167页码:115556 |
| ISSN号 | 1950-6007 |
| 关键词 | Active learning Consensus labelling Eye irritation Serious eye damage Structural alerts |
| DOI | 10.1016/j.biopha.2023.115556 |
| 文献子类 | Article |
| 英文摘要 | Asthma is a complex and heterogeneous respiratory disease that causes serious social and economic burdens. Current drugs such as beta2-agonists cannot fully control asthma. Our previous study found that Transgelin-2 is a potential target for treating asthmatic pulmonary resistance. Herein, we discovered a zolinium compound, TSG1180, that showed a strong interaction with Transgelin-2. The equilibrium dissociation constants (KD) of TSG1180 to Transgelin-2 were determined to be 5.363*10-6 and 9.81*10-6 M by surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC). Cellular thermal shift assay (CETSA) results showed that the thermal stability of Transgelin-2 increased after coincubation of TSG1180 with lysates of airway smooth muscle cells (ASMCs). Molecular docking showed that Arg39 may be the key residue for the binding. Then, the SPR result showed that the binding affinity of TSG1180 to Transgelin-2 mutant (R39E) was decreased by 1.69-fold. Real time cell analysis (RTCA) showed that TSG1180 treatment could relax ASMCs by 19 % (P<0.05). Once Transgelin-2 was inhibited, TSG1180 cannot induce a relaxation effect, suggesting that the relaxation effect was specifically mediated by Transgelin-2. In vivo study showed TSG1180 effectively reduced pulmonary resistance by 64 % in methacholine-induced mice model (P<0.05). Furthermore, the phosphorylation of Ezrin at T567 was increased by 8.06-fold, the phosphorylation of ROCK at Y722 was reduced by 38 % and the phosphorylation of RhoA at S188 was increased by 52 % after TSG1180 treatment. These results suggested that TSG1180 could be a Transgelin-2 agonist for further optimization and development as an anti-asthma drug. |
| WOS关键词 | Agonist ; Asthma ; Ezrin ; Mechanism ; Molecular docking ; Transgelin-2 |
| 语种 | 英语 |
| WOS记录号 | MEDLINE: 37778269 |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/309613]  |
| 专题 | 新药研究国家重点实验室 |
| 通讯作者 | Yang, Yong-Qing; Zhu, Weiliang; Yin, Lei-Miao |
| 作者单位 | 1.Yueyang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200030, China 2.Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China 3.State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China 4.School of Pharmacy, University of Chinese Academy of Sciences, Beijing 100049, China |
| 推荐引用方式 GB/T 7714 | Yuan, Hong-Kai,Li, Bo,Wu, Leyun,et al. Discovery of zolinium TSG1180 as a novel agonist of transgelin-2 for treating asthma[J]. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,2023,167:115556. |
| APA | Yuan, Hong-Kai.,Li, Bo.,Wu, Leyun.,Wang, Xue-Ling.,Lv, Zhi-Ying.,...&Yin, Lei-Miao.(2023).Discovery of zolinium TSG1180 as a novel agonist of transgelin-2 for treating asthma.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,167,115556. |
| MLA | Yuan, Hong-Kai,et al."Discovery of zolinium TSG1180 as a novel agonist of transgelin-2 for treating asthma".Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 167(2023):115556. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。